Idera Pharmaceuticals, Inc. (IDRA), a biotechnology company, announced on Monday preclinical results from novel Toll-like Receptor, or TLR, antagonist candidates for the treatment of lung inflammation and psoriasis.
The first study, which evaluated a TLR antagonist candidate for its anti-inflammatory activity in ovalbumin, or OVA,-induced lung inflammation in mice, suggests that TLR antagonists may have the potential to treat lung inflammatory diseases.
Results from the study showed significant reductions in parameters of inflammatory response, including production of IL-5, IL-13, IgE, and decreased numbers of inflammatory cells and mucin secreting cells in the lungs compared to mice treated with OVA alone.
Results from another study, which evaluated a TLR antagonist in a mouse model of psoriasis induced by administration of recombinant murine IL-23, demonstrated dose-dependent reductions in markers of IL-23-induced psoriasis, including epidermal hyperplasia, inflammatory cell infiltration, and IL-6 induction in dermal tissues, compared to mice treated with IL-23 alone.
Idera Pharma's stock is currently trading at $13.55, down 56 cents or 3.97%.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.